pharma · Duchenne Muscular Dystrophy · Duchenne Muscular Dystrophy (DMD) · TRDA
Entrada Therapeutics
Entrada Therapeutics patent portfolio — 5 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Boston, USA
- Founded
- 2016
- Employees
- 201
- Programs
- 4
- Drugs
- 4
- Patents
- 5
Entrada Therapeutics patents
5 pharmaceutical patents indexed for Entrada Therapeutics. 0 expire within 24 months.
Entrada Therapeutics has 5 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 11987821
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
granted -
US 11225506
Cell penetrating peptides and methods of making and using thereof
granted -
US 11168310
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
granted -
US 10815276
Cell penetrating peptides and methods of making and using thereof
granted -
US 10626147
Cell penetrating peptides and methods of making and using thereof
granted
Frequently asked questions
How many patents does Entrada Therapeutics have?
5 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Entrada Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.